Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The skin, as an organ in combination with a large number of commensal bacteria that colonized its surface and hair follicles, should be considered as a full-fledged and complex ecosystem. The imbalance of the skin microbiome can lead to skin diseases. The proportion of pyoderma among all skin pathology ranges from 17 to 36% among the population of the Russian Federation. Most skin infections occur de novo, but pyoderma often occurs when exposed to predisposing factors (for example, a violation of the skin barrier, the presence of maceration, old age, diabetes mellitus, obesity, peripheral arteriovenous insufficiency, corticosteroid treatment or chemotherapy, dysglobulinemia, blood diseases, cachexia, congenital or acquired immunodeficiency). Staphylococcus aureus and Streptococcus spp. they are the cause of most pyoderma. In patients undergoing long-term hospital treatment, S. aureus, P. aeruginosa, Enterococcus spp. and Escherichia coli are often the causative agents of skin infections. In localized, uncomplicated superficial pyoderma, local therapy is most often used. Dioxidin® is a derivative of di-N-oxy quinoxaline, a synetic broad-spectrum bactericidal drug that has been actively used by otolaryngologists and surgeons since 1976 to combat various bacterial infections. The drug is produced in the form of an aqueous solution for intravenous and intracavitary administration, as well as in the form of new dosage forms for topical and external use. Dioxidin is characterized by high bactericidal activity against a wide range of microorganisms, including anaerobic ones, and also acts against Candida albicans. This drug is able to completely suppress microorganisms with acquired resistance to antimicrobial drugs of other classes, including multiresistant strains. Dioxidine® in a new dosage form (0.25 mg/ml solution for topical and external use) has shown high efficacy when applied cutaneous to superficial pyoderma.
The skin, as an organ in combination with a large number of commensal bacteria that colonized its surface and hair follicles, should be considered as a full-fledged and complex ecosystem. The imbalance of the skin microbiome can lead to skin diseases. The proportion of pyoderma among all skin pathology ranges from 17 to 36% among the population of the Russian Federation. Most skin infections occur de novo, but pyoderma often occurs when exposed to predisposing factors (for example, a violation of the skin barrier, the presence of maceration, old age, diabetes mellitus, obesity, peripheral arteriovenous insufficiency, corticosteroid treatment or chemotherapy, dysglobulinemia, blood diseases, cachexia, congenital or acquired immunodeficiency). Staphylococcus aureus and Streptococcus spp. they are the cause of most pyoderma. In patients undergoing long-term hospital treatment, S. aureus, P. aeruginosa, Enterococcus spp. and Escherichia coli are often the causative agents of skin infections. In localized, uncomplicated superficial pyoderma, local therapy is most often used. Dioxidin® is a derivative of di-N-oxy quinoxaline, a synetic broad-spectrum bactericidal drug that has been actively used by otolaryngologists and surgeons since 1976 to combat various bacterial infections. The drug is produced in the form of an aqueous solution for intravenous and intracavitary administration, as well as in the form of new dosage forms for topical and external use. Dioxidin is characterized by high bactericidal activity against a wide range of microorganisms, including anaerobic ones, and also acts against Candida albicans. This drug is able to completely suppress microorganisms with acquired resistance to antimicrobial drugs of other classes, including multiresistant strains. Dioxidine® in a new dosage form (0.25 mg/ml solution for topical and external use) has shown high efficacy when applied cutaneous to superficial pyoderma.
Improving the effectiveness of treatment of patients with acute infectious and inflammatory pharyngeal diseases remains one of the topical issues facing the modern healthcare practice covering otorhinolaryngology, paediatrics and internal medicine sectors. The authors described the clinical picture of acute tonsillopharyngitis of various origin, and pharyngeal presentations in novel coronavirus infection. The article summarizes the modern principles of topical and systemic therapy in infectious and inflammatory pharyngeal pathology according to different etiological factors. Expedience of using topical antiseptic drugs as symptomatic therapy has been substantiated. The article examines in detail topical drugs that allow to achieve the maximum active substance concentration of the site of inflammation without systemic effect on the patient. The therapeutic options of topical antiseptic drugs are demonstrated using the example of Faringazon (active substance – ambazon) with local bacteriostatic effects against gram-positive microorganisms: Streptococcus haemolyticus, Streptococcus viridans, Pneumococcus. Most patients with inflammatory pharyngeal diseases do not require systemic antimicrobial therapy, therefore the local effect that can relieve local symptoms of the disease, return the pharyngoscopic picture to normal and improve patients’ general well-being is the main method of treatment. Symptomatic topical therapy as a component of care bundle for acute infectious and inflammatory pharyngeal diseases can significantly ease patients’ condition, reduce the intensity of pain syndrome and accelerate the eradication of pathogens. The use of Faringazon in wide clinical practice is justified owing to its efficiency and ease of administration. It is necessary to emphasize that Faringazon does not cause GI side effects. Exceptions are cases when the patients have individual intolerance to the active substance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.